Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

41. Statins in secondary cardiovascular prevention

Statins in secondary cardiovascular prevention Prescrire IN ENGLISH - Spotlight ''Statins in secondary cardiovascular prevention'', 1 September 2017 {1} {1} {1} | | > > > Statins in secondary cardiovascular prevention Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Statins in secondary cardiovascular prevention FEATURED REVIEW What is the evidence (...) for the efficacy of statins in secondary cardiovascular prevention? In which situations are they effective? What are their harms? To answer these questions, we reviewed the available evidence using the standard Prescrire methodology. Free abstract available here; full review (8 pages) available for download by subscribers. Abstract For patients who have already had a cardiovascular event or who have stable angina or peripheral artery disease, the prevention of cardiovascular events ("secondary prevention

2017 Prescrire

42. Guideline-Based Statin Eligibility, Cancer Events, and Noncardiovascular Mortality in the Framingham Heart Study Full Text available with Trip Pro

Guideline-Based Statin Eligibility, Cancer Events, and Noncardiovascular Mortality in the Framingham Heart Study Purpose Cancer and cardiovascular disease share risk factors, and there is some evidence that statins reduce cancer mortality. We sought to determine the accuracy of the 2013 American College of Cardiology/American Heart Association statin eligibility criteria to identify individuals at a higher risk of developing cancer or of dying as a result of cancer or other noncardiovascular (...) causes. Methods We included 2,196 participants (50.5 ± 8.1 years of age; 55% female) who were statin naïve and free of cancer at baseline from the offspring and third-generation cohorts of the community-based longitudinal Framingham Heart Study. Statin eligibility was determined per American College of Cardiology/American Heart Association guidelines, and subclinical coronary atherosclerosis was assessed by computed tomography. The primary outcome was incident cancer at a median of 10.0 years

2017 EvidenceUpdates

43. Comparison of Low-Dose Statin Versus Low-Dose Statin + Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial) (Abstract)

Comparison of Low-Dose Statin Versus Low-Dose Statin + Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial) Low-density lipoprotein cholesterol (LDL-C) reduction is associated with a significant decrease in mortality, and statins represent the most effective drugs to achieve this. However, side effects of statins are very common and may lead to treatment discontinuation. Nutraceuticals (...) are a combination of natural components that have shown efficacy in lowering LDL-C concentration when used alone or in association with other agents in patients who are intolerant to high-dose statins. Our aim was to compare the efficacy and tolerability of low-dose statin (LDS) therapy versus combined therapy of LDS plus a nutraceutical combination containing red yeast rice, policosanol, berberine, folic acid, coenzyme Q10 and astaxanthin (Armolipid Plus) in high-risk patients. We performed a randomized (1:1

2017 EvidenceUpdates

44. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. Full Text available with Trip Pro

Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. Some cholesteryl ester transfer protein (CETP) inhibitors lower low-density lipoprotein cholesterol (LDL-C) levels without reducing cardiovascular events, suggesting that the clinical benefit of lowering LDL-C may depend on how LDL-C is lowered.To estimate the association between changes in levels of LDL-C (and other lipoproteins) and the risk of cardiovascular events related (...) to variants in the CETP gene, both alone and in combination with variants in the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) gene.Mendelian randomization analyses evaluating the association between CETP and HMGCR scores, changes in lipid and lipoprotein levels, and the risk of cardiovascular events involving 102 837 participants from 14 cohort or case-control studies conducted in North America or the United Kingdom between 1948 and 2012. The associations with cardiovascular events were externally

2017 JAMA

45. Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study (Abstract)

Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study To examine the association between the use of statins and the risk of systemic lupus erythematosus (SLE) with focus on describing the patterns of risks over time.A population-based cohort study using the UK Clinical Practice Research Datalink.All patients aged 40 years or older who had at least one prescription of statins during the period 1995-2009 were selected and matched by age, sex (...) , practice and date of first prescription to non-users. The follow-up period of statin users was divided into periods of current, recent and past exposure, with patients moving among these three exposure categories over time. Current statin users were also stratified into ≤1 year or >1 year of use.Time-dependent Cox models were used to calculate HRs of SLE, adjusted for disease history and previous drug exposure.We included 1 039 694 patients, of whom 519 847 were statin users. Current statin users did

2017 EvidenceUpdates

46. Continued Statin Prescriptions After Adverse Reactions and Patient Outcomes: A Cohort Study. (Abstract)

Continued Statin Prescriptions After Adverse Reactions and Patient Outcomes: A Cohort Study. Many patients discontinue statin treatment, often after having a possible adverse reaction. The risks and benefits of continued statin therapy after an adverse reaction are not known.To examine the relationship between continuation of statin therapy (any prescription within 12 months after an adverse reaction) and clinical outcomes.Retrospective cohort study.Primary care practices affiliated with 2 (...) academic medical centers.Patients with a presumed adverse reaction to a statin between 2000 and 2011.Information on adverse reactions to statins was obtained from structured electronic medical record data or natural-language processing of narrative provider notes. The primary composite outcome was time to a cardiovascular event (myocardial infarction or stroke) or death.Most (81%) of the adverse reactions to statins were identified from the text of electronic provider notes. Among 28 266 study patients

2017 Annals of Internal Medicine

47. A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol Full Text available with Trip Pro

A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol This phase 3, multiregional, randomized, double-blind, placebo-controlled study assessed the efficacy/safety profile of anacetrapib added to ongoing therapy with statin ± other lipid-modifying therapies in patients with hypercholesterolemia who were not at their low-density (...) lipoprotein (LDL-C) goal (as per the National Cholesterol Education Program Adult Treatment Panel III guidelines) and in those with low high-density lipoprotein cholesterol (HDL-C). Patients on a stable dose of statin ± other lipid-modifying therapies and with LDL-C ≥70 to <115, ≥100 to <145, ≥130, or ≥160 mg/dl for very high, high, moderate, or low CHD risk or at LDL-C goal (per CHD risk category) with HDL-C ≤40 mg/dl were randomized in a ratio of 1:1 to anacetrapib 100 mg (n = 290) or placebo (n = 293

2017 EvidenceUpdates

48. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension p Full Text available with Trip Pro

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension p In blinded randomised controlled trials, statin therapy has been associated with few adverse events (AEs). By contrast, in observational studies, larger increases in many different AEs have been reported than in blinded trials.In the Lipid (...) -Lowering Arm of the Anglo-Scandinavian Cardiac Outcomes Trial, patients aged 40-79 years with hypertension, at least three other cardiovascular risk factors, and fasting total cholesterol concentrations of 6·5 mmol/L or lower, and who were not taking a statin or fibrate, had no history of myocardial infarction, and were not being treated for angina were randomly assigned to atorvastatin 10 mg daily or matching placebo in a randomised double-blind placebo-controlled phase. In a subsequent non-randomised

2017 Lancet Controlled trial quality: predicted high

49. Do statins adversely affect the HbA1c of diabetic patients? Full Text available with Trip Pro

Do statins adversely affect the HbA1c of diabetic patients? This paper discusses the adverse effect of statins on the HbA1c levels of diabetic patients. Studies have shown that statins may slightly worsen the HbA1c level. The effects vary depending on the type of statins, the dosage and the duration of therapy. However, it has been confirmed that statin use has benefits that outweigh its harms. Therefore, a diabetic patient should be given advice on the need for appropriate lifestyle changes (...) and the importance of continuing the statins.

2017 Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia

50. Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries Full Text available with Trip Pro

Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries High-intensity statins are recommended following myocardial infarction. However, patients may not continue taking this medication with high adherence.To estimate the proportion of patients filling high-intensity statin prescriptions following myocardial infarction who continue taking this medication with high adherence and to analyze factors associated with continuing a high (...) -intensity statin with high adherence after myocardial infarction.Retrospective cohort study of Medicare patients following hospitalization for myocardial infarction. Medicare beneficiaries aged 66 to 75 years (n = 29 932) and older than 75 years (n = 27 956) hospitalized for myocardial infarction between 2007 and 2012 who filled a high-intensity statin prescription (atorvastatin, 40-80 mg, and rosuvastatin, 20-40 mg) within 30 days of discharge. Beneficiaries had Medicare fee-for-service coverage

2017 JAMA cardiology

51. Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines. Full Text available with Trip Pro

Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines. There are important differences among guideline recommendations for using statin therapy in primary prevention. New recommendations from the US Preventive Services Task Force (USPSTF) emphasize therapy based on the presence of 1 or more cardiovascular disease (CVD) risk factors and a 10-year global CVD risk of 10% or greater.To (...) determine the difference in eligibility for primary prevention statin treatment among US adults, assuming full application of USPSTF recommendations compared with the American College of Cardiology/American Heart Association (ACC/AHA) guidelines.National Health and Nutrition Examination Survey (NHANES) data (2009-2014) were used to assess statin eligibility under the 2016 USPSTF recommendations vs the 2013 ACC/AHA cholesterol guidelines among a nationally representative sample of 3416 US adults aged 40

2017 JAMA

52. Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African American Individuals: The Jackson Heart Study Full Text available with Trip Pro

Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African American Individuals: The Jackson Heart Study Modern prevention guidelines substantially increase the number of individuals who are eligible for treatment with statins. Efforts to refine statin eligibility via coronary calcification have been studied in white populations but not, to our knowledge, in large African American populations.To compare the relative accuracy of US Preventive Services Task Force (USPSTF (...) , and incident ASCVD (ie, myocardial infarction, ischemic stroke, or fatal coronary heart disease).Of the 2812 included participants, the mean (SD) age at baseline was 55.4 (9.4) years, and 1837 (65.3%) were female. The USPSTF guidelines captured 404 of 732 African American individuals (55.2%) with a CAC score greater than 0; the ACC/AHA guidelines identified 507 individuals (69.3%) (risk difference, 14.1%; 95% CI, 11.2-17.0; P < .001). Statin recommendation under both guidelines was associated with a CAC

2017 JAMA cardiology

53. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. Full Text available with Trip Pro

Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. Patients with type 2 diabetes are at high risk of cardiovascular disease (CVD) in part owing to hypertriglyceridemia and low high-density lipoprotein cholesterol. It is unknown whether adding triglyceride-lowering treatment to statin reduces this risk.To determine whether fenofibrate reduces CVD risk in statin-treated patients with type 2 diabetes.Posttrial follow-up

2017 JAMA cardiology Controlled trial quality: predicted high

54. Statins for primary and secondary prevention of cardiovascular disease

Statins for primary and secondary prevention of cardiovascular disease

2017 DynaMed Plus

58. Non-Statin Therapies For LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

-effectiveness estimates were also provided. These considerations may help clinicians and patients to quantify the potential bene?ts of adding ezetimibe therapy or PCSK9 inhibitors in secondary pre- vention and in primary prevention among patients with LDL-C$190 mg/dL. Based on the important evidence of signi?cant bene?tin cardiovascular event reduction with the addition of evolo- cumab to maximally tolerated statin, with or without eze- timibe, and other new perspectives reviewed in the previous text (...) interactions, and consider patient prefer- ences. The interindividual variability in response to evo- locumab has not been reported. It is reasonable to engage in aclinician–patientdiscussionwith consideration of net risk reduction bene?ts of a PCSK9 inhibitor, cost, administration by subcutaneous injection, every 14-day or monthly dosing schedule, and storage requirements (refrigeration). If a PCSK9 inhibitor is prescribed, clini- cians should continue maximally tolerated statin and monitoring

2017 American College of Cardiology

59. Perspective on Trends in Statin Use Full Text available with Trip Pro

Perspective on Trends in Statin Use 27842177 2018 11 13 2380-6591 2 1 2017 Jan 01 JAMA cardiology JAMA Cardiol Perspective on Trends in Statin Use. 11-12 10.1001/jamacardio.2016.4710 Weintraub William S WS Christian Care Health System, Newark, Delaware. eng U54 GM104941 GM NIGMS NIH HHS United States Journal Article United States JAMA Cardiol 101676033 2016 11 15 6 0 2016 11 15 6 0 2016 11 15 6 0 ppublish 27842177 2583423 10.1001/jamacardio.2016.4710 PMC5621636 NIHMS863753 Health Aff (Millwood

2017 JAMA cardiology

60. Unblinded ASCOT study results do not rule out that muscle symptoms are an adverse effect of statins

Unblinded ASCOT study results do not rule out that muscle symptoms are an adverse effect of statins Unblinded ASCOT study results do not rule out that muscle symptoms are an adverse effect of statins | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Unblinded ASCOT study results do not rule out that muscle symptoms are an adverse effect of statins Article Text Commentary: General medicine Unblinded ASCOT study results do not rule out

2017 Evidence-Based Medicine